Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: A meta-analysis

Journal of the National Cancer Institute

Volumn 103, Issue 2, 2011, Pages 129-142

  Xing, Yan ^a   Bronstein, Yulia ^a   Ross, Merrick I ^a   Askew, Robert L ^a   Lee, Jeffrey E ^a   Gershenwald, Jeffrey E ^a   Royal, Richard ^a   Cormier, Janice N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; ECHOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

BAYES THEOREM; HUMANS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; ODDS RATIO; POPULATION SURVEILLANCE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 79251482754     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq455     Document Type: Article

References (151)

1. American Joint Committee on Cancer. Melanoma of the Skin. In: Edge SB, Byrd DR, Compton CC, et al. eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009;325-344.
2. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician-gls/def/ault.asp.
3. Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006;24(18):2858-2865.
4. Balch CM, Cascinelli N. Sentinel-node biopsy in melanoma. N Engl J Med. 2006;355(13):1370-1371.
5. Sanki A, Uren RF, Moncrieff M, et al. Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol. 2009; 27(33):5614-5619.
6. Voit CA, van Akkooi AC, Schafer-Hesterberg G, et al. Rotterdam criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fne-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol. 2009; 27(30):4994-5000.
7. Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of (18)F-fuorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001; 91(8):1530-1542.
8. Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med. 2000;44(2):153-167. (Pubitemid 30623521)
9. Krug B, Crott R, Lonneux M, et al. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology. 2008; 249(3):836-844.
10. El-Maraghi RH, Kielar AZ. PET vs sentinel lymph node biopsy for staging melanoma: a patient intervention, comparison, outcome analysis. J Am Coll Radiol. 2008;5(8):924-931.
11. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. http://seer.cancer.gov/csr/1975-2006/. Accessed November 1, 2008.
12. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53(1):5-26.
13. Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86(4):172-178.
14. Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on cancer stages I-III malignant melanoma. Cancer. 1999;86(11):2252-2258.
15. MacCormack MA, Cohen LM, Rogers GS. Local melanoma recurrence: a clarifcation of terminology. Dermatol Surg. 2004;30(12, pt 2):1533-1538.
16. McEwan L, Smith JG, Matthews JP. Late recurrence of localized cutaneous melanoma: its infuence on follow-up policy. Plast Reconstr Surg. 1990;86:527.
17. Slingluff CL Jr., Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer. 1992; 70(7):1917-1927.
18. Romero JB, Stefanato CM, Kopf AW, Bart RS. Follow-up recommendations for patients with stage I malignant melanoma. J Dermatol Surg Oncol. 1994;20(3):175-178.
19. Benvenuto-Andrade C, Oseitutu A, Agero AL, Marghoob AA. Cutaneous melanoma: surveillance of patients for recurrence and new primary melanomas. Dermatol Ther. 2005;18(6):423-435.
20. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol. 1998;67(4):228-233.
21. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002; 147(1):62-70.
22. Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Br J Dermatol. 1999;140:249-254.
23. Petersen RP, Hanish SI, Haney JC, et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary meta-static melanoma. J Thorac Cardiovasc Surg. 2007;133(1):104-110.
24. Andrews S, Robinson L, Cantor A, DeConti RC. Survival after surgical resection of isolated pulmonary metastases from malignant melanoma. Cancer Control. 2006;13(3):218-223.
25. DiLuna ML, King JT Jr., Knisely JP, Chiang VL. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases. Cancer. 2007;109(1):135-145.
26. Young SE, Martinez SR, Essner R. The role of surgery in treatment of stage IV melanoma. J Surg Oncol. 2006;94(4):344-351.
27. Riker AI, Kirksey L, Thompson L, Morris A, Cruse CW. Current surgical management of melanoma. Expert Rev Anticancer Ther. 2006;6(11): 1569-1583.
28. Garbe C, Paul A, Kohler-Spath H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21(3):520-529.
29. Rhodes AR. Cutaneous melanoma and intervention strategies to reduce tumor-related mortality: what we know, what we don't know, and what we think we know that isn't so. Dermatol Ther. 2006;19(1):50-69.
30. Popescu RA, Patel PM, Spencer J. Imaging and investigation of melanoma patients. In: Newton Bishop JA, Gore M, eds. Melanoma: Critical Debates .Oxford, UK: Blackwell Science Ltd; 2002:133-149.
31. Bafounta ML, Beauchet A, Chagnon S, Saiag P. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol. 2004;5(11):673-680.
32. Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Oncol Clin N Am. 2007;16(2):403-430.
33. Saiag P, Bernard M, Beauchet A, et al. Ultrasonography using simple diagnostic criteria vs palpation for the detection of regional lymph node metastases of melanoma. Arch Dermatol. 2005;141(2): 183-189.
34. Steinert HC, Voellmy DR, Trachsel C, et al. Planar coincidence scintig-raphy and PET in staging malignant melanoma. J Nucl Med. 1998;39(11): 1892-1897.
35. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
36. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specifcity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol. 2006;59(12):1331-1332; author reply 1332-1333.
37. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 56(11):1129-1135.
38. Dawson B, Trapp RG. Basic and Clinical Biostatistics. Norwalk, CT: Appleton & Lange; 1990.
39. Spiegelhalter D, Thomas A, Best NG. WinBUGS Version 1.4 User Manual. Cambridge, UK: MRC Biostatistics Unit; 2003.
40. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7:457-511.
41. Petitti DB. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis. 2nd ed. New York, NY: Oxford University Press; 2000.
42. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
43. Prayer L, Winkelbauer H, Gritzmann N, et al. Sonography versus palpation in the detection of regional lymph-node metastases in patients with malignant melanoma. Eur J Cancer. 1990;26(7):827-830.
44. Tregnaghi A, De Candia A, Calderone M, et al. Ultrasonographic evaluation of superfcial lymph node metastases in melanoma. Eur J Radiol. 1997;24(3):216-221.
45. Binder M, Kittler H, Steiner A, et al. Lymph node sonography versus palpation for detecting recurrent disease in patients with malignant melanoma. Eur J Cancer. 1997;33(11):1805-1808.
46. Uren RF, Howman-Giles R, Thompson JF, et al. High-resolution ultrasound to diagnose melanoma metastases in patients with clinically palpable lymph nodes. Australas Radiol. 1999;43(2):148-152.
47. Voit C, Mayer T, Kron M, et al. Effcacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients. Cancer. 2001;91(12):2409-2416.
48. Rossi CR, Scagnet B, Vecchiato A, et al. Sentinel node biopsy and ultrasound scanning in cutaneous melanoma: clinical and technical considerations. Eur J Cancer. 2000;36(7):895-900. (Pubitemid 30214140)
49. Brountzos EN, Panagiotou IE, Bafaloukos DI, Kelekis DA. Ultrasonographic detection of regional lymph node metastases in patients with intermediate or thick malignant melanoma. Oncol Rep. 2003; 10(2):505-510.
50. Schmid-Wendtner MH, Paerschke G, Baumert J, Plewig G, Volkenandt M. Value of ultrasonography compared with physical examination for the detection of locoregional metastases in patients with cutaneous melanoma. Melanoma Res. 2003;13(2):183-188.
51. Hafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol. 2004;150(4):677-686.
52. Hocevar M, Bracko M, Pogacnik A, et al. The role of preoperative ultra-sonography in reducing the number of sentinel lymph node procedures in melanoma. Melanoma Res. 2004;14(6):533-536.
53. Machet L, Nemeth-Normand F, Giraudeau B, et al. Is ultrasound lymph node examination superior to clinical examination in melanoma follow-up? A monocentre cohort study of 373 patients. Br J Dermatol. 2005; 152(1):66-70.
54. Starritt EC, Uren RF, Scolyer RA, Quinn MJ, Thompson JF. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol. 2005;12(1):18-23.
55. Testori A, Lazzaro G, Baldini F, et al. The role of ultrasound of sentinel nodes in the pre- and post-operative evaluation of stage I melanoma patients. Melanoma Res. 2005;15(3):191-198.
56. Voit C, Kron M, Schafer G, et al. Ultrasound-guided fne needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2006;13(12):1682-1689.
57. Dalle S, Paulin C, Lapras V, et al. Fine-needle aspiration biopsy with ultrasound guidance in patients with malignant melanoma and palpable lymph nodes. Br J Dermatol. 2006;155(3):552-556.
58. Sibon C, Chagnon S, Tchakerian A, et al. The contribution of high-resolution ultrasonography in preoperatively detecting sentinel-node metastases in melanoma patients. Melanoma Res. 2007;17(4):233-237.
59. Schmid-Wendtner MH, Dill-Muller D, Baumert J, et al. Lymph node metastases in patients with cutaneous melanoma: improvements in diagnosis by signal-enhanced color Doppler sonography. Melanoma Res. 2004;14(4):269-276.
60. Rossi CR, Mocellin S, Scagnet B, et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol. 2003;83(2):80-84.
61. van Rijk MC, Teertstra HJ, Peterse JL, et al. Ultrasonography and fne-needle aspiration cytology in the preoperative evaluation of melanoma patients eligible for sentinel node biopsy. Ann Surg Oncol. 2006;13(11): 1511-1516.
62. Schafer-Hesterberg G, Schoengen A, Sterry W, Voit C. Use of ultrasound to early identify, diagnose and localize metastases in melanoma patients. Expert Rev Anticancer Ther. 2007;7(12):1707-1716.
63. Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol. 1993;11(4):638-643.
64. Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol. 1995;13(8):2104-2108.
65. Kuvshinoff BW, Kurtz C, Coit DG, et al. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol. 1997;4(3):252-258.
66. Holder WD Jr. White RL Jr. Zuger JH, Easton EJ Jr. Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227(5):764-769. discussion 769-771.
67. Swetter SM, Carroll LA, Johnson DL, et al. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol. 2002;9(7):646-653.
68. Finkelstein SE, Carrasquillo JA, Hoffman JM, et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol. 2004;11(8):731-738.
69. Romer W, Nomayr A, Greess H, et al. Retrospective interactive rigid fusion of (18)F-FDG-PET and CT. Additional diagnostic information in melanoma patients. Nuklearmedizin. 2006;45(2):88-95.
70. Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative [(18)]f fuorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol. 2006;13(4):525-532.
71. Pfannenberg C, Aschoff P, Schanz S, et al. Prospective comparison of 18F-fuorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer. 2007;43(3):557-564.
72. Iagaru A, Quon A, Johnson D, Gambhir SS, McDougall IR. 2-Deoxy-2-[F-18]fuoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol. 2007;9(1):50-57.
73. Fuster D, Chiang S, Johnson G, et al. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med. 2004;45(8):1323-1327.
74. Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24(7):1178-1187.
75. Veit-Haibach P, Vogt FM, Jablonka R, et al. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging. 2009;36(6):910-918.
76. Gritters LS, Francis IR, Zasadny KR, et al. Initial assessment of positron emission tomography using 2-fuorine-18-fuoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34(9):1420-1427.
77. Boni R, Boni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fuorine-18-fuoro-2-deoxy-D- glucose. Br J Dermatol. 1995;132(4):556-562.
78. Blessing C, Feine U, Geiger L, et al. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol. 1995;131(12):1394-1398.
79. Steinert HC, Huch Boni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fuoro-2-deoxy-D- glucose. Radiology. 1995;195(3):705-709.
80. Damian DL, Fulham MJ, Thompson E, et al. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6(4):325-329.
81. Nguyen AT, Akhurst T, Larson SM, Coit DG, Brady MS. PET Scanning with (18)F 2-fuoro-2-deoxy-D-glucose (FDG) in patients with melanoma. Benefts and limitations. Clin Positron Imaging. 1999;2(2):93-98.
82. Jadvar H, Johnson DL, Segall GM, et al. The effect of fuorine-18 fuoro-deoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med. 2000;25(1):48-51.
83. Eigtved A, Andersson AP, Dahlstrom K, et al. Use of fuorine-18 fuoro-deoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med. 2000;27(1): 70-75.
84. Paquet P, Henry F, Belhocine T, et al. An appraisal of 18-fuorodeoxyglu-cose positron emission tomography for melanoma staging. Dermatology. 2000;200(2):167-169.
85. Acland KM, O'Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol. 2000;42(4):606-611.
86. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89(5):1019-1025.
87. Klein M, Freedman N, Lotem M, et al. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma. A pilot study. Nucl Med (Stuttg). 2000;39(3):56-61.
88. Stas M, Stroobants S, Dupont P, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res. 2002;12(5):479-490.
89. Cobben DC, Jager PL, Elsinga PH, et al. 3'-18F-fuoro-3'-deoxy-L- thymidine: a new tracer for staging metastatic melanoma? J Nucl Med. 2003;44(12):1927-1932.
90. Gulec SA, Faries MB, Lee CC, et al. The role of fuorine-18 deoxyglucose positron emission tomography in the management of patients with meta-static melanoma: impact on surgical decision making. Clin Nucl Med. 2003;28(12):961-965.
91. Reinhardt MJ, Kensy J, Frohmann JP, et al. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Nuklearmedizin. 2002;41(3):143-147.
92. Harris MT, Berlangieri SU, Cebon JS, Davis ID, Scott AM. Impact of 2-deoxy-2[F-18]fuoro-D-glucose positron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol. 2005;7(4):304-308.
93. Horn J, Lock-Andersen J, Sjostrand H, Loft A. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging. 2006;33(8):887-892.
94. Mottaghy FM, Sunderkotter C, Schubert R, et al. Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging. 2007;34(9):1355-1364.
95. Koskivuo IO, Seppanen MP, Suominen EA, et al. Whole body positron emission tomography in follow-up of high risk melanoma. Acta Oncol. 2007;46(5):685-690.
96. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fuorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer. 1998;82(9):1664-1671.
97. Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998;16(5):1770-1776.
98. Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med. 2000; 41(9):1491-1494.
99. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micro-metastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001; 19(10):2674-2678.
100. Kokoska MS, Olson G, Kelemen PR, et al. The use of lymphoscintigraphy and PET in the management of head and neck melanoma. Otolaryngol Head Neck Surg. 2001;125(3):213-220.
101. Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist. 2002;7(4):271-278.
102. Longo MI, Lazaro P, Bueno C, et al. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg. 2003;29(3): 245-248.
103. Havenga K, Cobben DC, Oyen WJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol. 2003;29(8):662-664.
104. Fink AM, Holle-Robatsch S, Herzog N, et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res. 2004;14(2):141-145.
105. Wagner JD, Schauwecker D, Davidson D, et al. Ineffcacy of F-18 fuoro-deoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104(3):570-579.
106. Vereecken P, Laporte M, Petein M, Steels E, Heenen M. Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. J Eur Acad Dermatol Venereol. 2005;19(1):66-73.
107. Bastiaannet E, Oyen WJ, Meijer S, et al. Impact of [18F]fuorodeoxyglu- cose positron emission tomography on surgical management of melanoma patients. Br J Surg. 2006;93(2):243-249.
108. Clark PB, Soo V, Kraas J, Shen P, Levine EA. Futility of fuorodeoxyglu-cose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg. 2006;141(3):284-288.
109. Maubec E, Lumbroso J, Masson F, et al. F-18 fuorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res. 2007;17(3): 147-154.
110. Akcali C, Zincirkeser S, Erbagcy Z, et al. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT. J Int Med Res. 2007;35(4):547-553.
111. Strobel K, Skalsky J, Kalff V, et al. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging. 2007;34(9):1366-1375.
112. Falk MS, Truitt AK, Coakley FV, et al. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma. Nucl Med Commun. 2007;28(4):273-280.
113. Kell MR, Ridge JA, Joseph N, et al. PET CT imaging in patients undergoing sentinel node biopsy for melanoma. Eur J Surg Oncol. 2007;33(7): 911-913.
114. Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer. 2007;110(5):1107-1114.
115. Singh B, Ezziddin S, Palmedo H, et al. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Res. 2008;18(5):346-352.
116. Tsao MN, Lloyd NS, Wong RK. Clinical practice guideline on the optimal radiotherapeutic management of brain metastases. BMC Cancer. 2005;5(1):34.
117. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21. March 2004, under the auspices of ESMO. Ann Oncol. 2005;16(4):566-578.
118. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol. 2005;23(9):2028-2037.
119. Fervers B, Burgers JS, Haugh MC, et al. Predictors of high quality clinical practice guidelines: examples in oncology. Int J Qual Health Care. 2005; 17(2):123-132.
120. Im SS, Gordon AN, Buttin BM, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol. 2005;105(1):35-41.
121. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004;22(24): 4979-4990.
122. Kuehn T, Bembenek A, Decker T, et al. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer. 2005;103(3): 451-461.
123. Schulz KD, Koller M, Lorenz W, et al. [Short version of the guideline "Early Detection of Breast Cancer in Germany"]. Z Arztl Fortbild Qualitatssich. 2004;98(5):361-373.
124. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138(2):90-97.
125. Barzilai DA, Cooper KD, Neuhauser D, Rimm AA, Cooper GS. Geographic and patient variation in receipt of surveillance procedures after local excision of cutaneous melanoma. J Invest Dermatol. 2004; 122(2):246-255.
126. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6(8):608-621.
127. Virgo KS, Chan D, Handler BS, et al. Current practice of patient follow-up after potentially curative resection of cutaneous melanoma. Plast Reconstr Surg. 2000;106(3):590-597.
128. Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer. 1997;80(6):1052-1064.
129. Deurloo EE, Tanis PJ, Gilhuijs KG, et al. Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer. 2003;39(8):1068-1073.
130. Motomura K, Inaji H, Komoike Y, et al. Gamma probe and ultrasonographically-guided fne-needle aspiration biopsy of sentinel lymph nodes in breast cancer patients. Eur J Surg Oncol. 2001;27(2):141-145.
131. Voit C, Mayer T, Proebstle TM, et al. Ultrasound-guided fne-needle aspiration cytology in the early detection of melanoma metastases. Cancer. 2000;90(3):186-193.
132. Bastiaannet E, Wobbes T, Hoekstra OS, et al. Prospective comparison of [18F]fuorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metas-tases: diagnostic accuracy and impact on treatment. J Clin Oncol. 2009; 27(28):4774-4780.
133. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg. 1995;221(5):566-569.
134. Halpern AC, Mandal SK. Role of dermatologists in treating melanoma. J Natl Compr Canc Netw. 2006;4(7):695-702.
135. Hillman BJ. Self-referral: the time for whining is over. J Am Coll Radiol. 2004;1(11):795-796.
136. Pearson SD, Knudsen AB, Scherer RW, Weissberg J, Gazelle GS. Assessing the comparative effectiveness of a diagnostic technology: CT colonography. Health Aff (Millwood). 2008;27(6):1503-1514.
137. Earle CC, Park ER, Lai B, et al. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003;21(6):1133-1138.
138. Lohr K. Medicare: A Strategy for Quality Assurance. Washington, DC: National Academy Press; 1990.
139. McColl A, Roderick P, Gabbay J, Smith H, Moore M. Performance indicators for primary care groups: an evidence based approach. BMJ. 1998;317(7169):1354- 1360.
140. National Cancer Policy Board Institute of Medicine and National Research Council. Ensuring Quality Cancer Care. Washington, DC: National Academy Press 1999.
141. Mortenson LE. How to judge the cancer services beneft component of your health insurance plan. Cancer. 1998;82(10) (suppl):2061-2067.
142. Dunnick NR, Applegate KE, Arenson RL. The inappropriate use of imaging studies: a report of the 2004 Intersociety Conference. J Am Coll Radiol. 2005;2(5):401-406.
143. Lysdahl KB, Hofmann BM. What causes increasing and unnecessary use of radiological investigations? A survey of radiologists' perceptions. BMC Health Serv Res. 2009;9:155.
144. Studdert DM, Mello MM, Sage WM, et al. Defensive medicine among high-risk specialist physicians in a volatile malpractice environment. JAMA. 2005;293(21):2609-2617.
145. Wilson IB, Dukes K, Greenfeld S, Kaplan S, Hillman B. Patients' role in the use of radiology testing for common offce practice complaints. Arch Intern Med. 2001;161(2):256-263.
146. Berrington de Gonzalez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22):2071-2077.
147. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169(22): 2078-2086.
148. Gottlieb RH. Imaging for whom: patient or physician? AJR Am J Roentgenol. 2005;185(6):1399-1403.
149. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specifcity with sparse data: a generalized linear mixed model approach. J Clin Epidemiol. 2006;59(12):1331-1332; author reply 1332-1333.
150. Harbord RM, Whiting P, Sterne JA, et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol. 2008;61(11):1095-1103.
151. Thornbury JR, Eugene W. Caldwell Lecture. Clinical effcacy of diagnostic imaging: love it or leave it. AJR Am J Roentgenol. 1994;162(1):1-8.